3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Pancreatic Neoplasms
10
Breast Neoplasms
8
Colorectal Neoplasms
7
Prostatic Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Neoplasms
4
Melanoma
4
COVID-19
4
Multiple Myeloma
3
Lung Neoplasms
3
Colonic Neoplasms
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Solid Tumor
2
Recurrence
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Neoplasms, Plasma Cell
2
Neoplasm Metastasis
2
Leukemia
2
Glioblastoma
2
Gastrointestinal Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma of Lung
2
Adenocarcinoma
2
Urologic Diseases
1
Untreated Resectable Pancreatic Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Resectable Localized Prostate Cancer
1
Refractory or Relapsed Solid Tumors
1
Interventions
Cyclophosphamide
72
fludarabine
65
Tacrolimus
43
fludarabine phosphate
40
Whole-Body Irradiation
37
Mycophenolic Acid
35
Busulfan
32
Melphalan
28
Antilymphocyte Serum
23
thymoglobulin
22
Thiotepa
20
Methotrexate
20
Standard of Care
19
Stem Cell Transplantation
17
Practice Guidelines as Topic
17
Granulocyte Colony-Stimulating Factor
17
Rituximab
15
Surveys and Questionnaires
12
Sirolimus
12
Filgrastim
12
Interviews as Topic
11
Cyclosporine
11
Blood Specimen Collection
11
Peripheral Blood Stem Cell Transplantation
10
Exercise
10
venetoclax
9
Mesna
9
Cytarabine
9
Bortezomib
9
Hematopoietic Stem Cell Transplantation
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Hematologic Neoplasms
×
Hydroxychloroquine
×
Clear all
NCT04392128
2020-09-04
HYACINTHE
Institut de cancérologie Strasbourg Europe
Phase 2
Withdrawn